Vis enkel innførsel

dc.contributor.authorFortner, KA
dc.contributor.authorBlanco, Luz P.
dc.contributor.authorBuskiewicz, I
dc.contributor.authorHuang, N
dc.contributor.authorGibson, PC
dc.contributor.authorCook, DL
dc.contributor.authorPedersen, Hege Lynum
dc.contributor.authorYuen, PST
dc.contributor.authorMurphy, MP
dc.contributor.authorPerl, A
dc.contributor.authorKaplan, Mariana J.
dc.contributor.authorBudd, RC
dc.date.accessioned2020-06-23T08:32:08Z
dc.date.available2020-06-23T08:32:08Z
dc.date.issued2020-04-16
dc.description.abstract<i>Objectives</i> - Recent investigations in humans and mouse models with lupus have revealed evidence of mitochondrial dysfunction and production of mitochondrial reactive oxygen species (mROS) in T cells and neutrophils. This can provoke numerous cellular changes including oxidation of nucleic acids, proteins, lipids and even induction of cell death. We have previously observed that in T cells from patients with lupus, the increased mROS is capable of provoking oligomerisation of mitochondrial antiviral stimulator (MAVS) and production of type I interferon (IFN-I). mROS in SLE neutrophils also promotes the formation of neutrophil extracellular traps (NETs), which are increased in lupus and implicated in renal damage. As a result, in addition to traditional immunosuppression, more comprehensive treatments for lupus may also include non-immune therapy, such as antioxidants.<p><p> <i>Methods</i> - Lupus-prone MRL-<i>lpr</i> mice were treated from weaning for 11 weeks with the mitochondria-targeted antioxidant, MitoQ (200 µM) in drinking water. Mice were then assessed for ROS production in neutrophils, NET formation, MAVS oligomerisation, serum IFN-I, autoantibody production and renal function.<p><p> <i>Results</i> - MitoQ-treated mice manifested reduced neutrophil ROS and NET formation, decreased MAVS oligomerisation and serum IFN-I, and reduced immune complex formation in kidneys, despite no change in serum autoantibody.<p><p> <i>Conclusions</i> - These findings reveal the potential utility of targeting mROS in addition to traditional immunosuppressive therapy for lupus.en_US
dc.identifier.citationFortner, Blanco LP, Buskiewicz, Huang N, Gibson, Cook, Pedersen hl, Yuen, Murphy, Perl, Kaplan MJ, Budd. Targeting mitochondrial oxidative stress with MitoQ reduces NET formation and kidney disease in lupus-prone MRL-lpr mice.. Lupus Science and Medicine. 2020en_US
dc.identifier.cristinIDFRIDAID 1815551
dc.identifier.doi10.1136/lupus-2020-000387
dc.identifier.issn2053-8790
dc.identifier.urihttps://hdl.handle.net/10037/18628
dc.language.isoengen_US
dc.publisherBMJ Publishing Groupen_US
dc.relation.journalLupus Science and Medicine
dc.rights.accessRightsopenAccessen_US
dc.rights.holderCopyright 2020 The Author(s)en_US
dc.subjectVDP::Medical disciplines: 700en_US
dc.subjectVDP::Medisinske Fag: 700en_US
dc.titleTargeting mitochondrial oxidative stress with MitoQ reduces NET formation and kidney disease in lupus-prone MRL-lpr miceen_US
dc.type.versionpublishedVersionen_US
dc.typeJournal articleen_US
dc.typeTidsskriftartikkelen_US
dc.typePeer revieweden_US


Tilhørende fil(er)

Thumbnail

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel